TP53 and acute lymphoblastic leukemia: More recently described cytogenetic subtypes with prognostic impact, such as Ph-like ALL, or secondary lesions such as TP53 and RAS mutations were not tested in this cohort but are being considered for new risk stratification algorithms [10, 34].